The past four years have shown tremendous advancement and innovation in the development of cell-based therapies to treat cancer, with approved therapies reaching the market and hundreds of clinical trials underway. In this experts panel discussion moderated by Dr. Qasim Rafiq, Associate Professor in Cell and Gene Therapy Bioprocess Engineering Department of Biochemical Engineering at University College London,  Dr. Devon Shedlock, Chief Scientific Officer, Cell Therapies at Poseida Therapeutics, and Dr. Wayne Chu, Senior Vice President of Clinical Development at Fate Therapeutics, share insights and perspectives on where the cellular immunotherapy industry is headed. 

Tune into the discussion to learn more about: 

• Multi-pronged approaches to optimizing cell therapies for increased effectiveness 

• Dose considerations for cell therapies  

• Different clinical and manufacturing implications of NK versus T cell-based products as well as T cell subtype ratio 

• Key critical quality attributes (CQAs) to ensure efficacy and safety of immune cell therapies 

Qasim Rafiq, Ph.D.
Associate Professor in Cell & Gene Therapy Bioprocess Engineering
University College London


Wayne Chu, M.D.

Senior Vice President, Clinical Development
Fate Therapeutics


Devon J. Shedlock, Ph.D.

Chief Scientific Officer, Cell Therapies
Poseida Therapeutics